CIAs pressure pharma to rethink sales rep compensation
Novartis’s recent off-label settlement with the Department of Justice — to the tune of $422 million — also included the signing of a Corporate Integrity Agreement (CIA) requiring the Swiss-based manufacturer to review incentive-based compensation for reps, and to examine “the extent to which compensation is based on product performance,” according to the CIA.